Burden of Antimicrobial Resistance in Japan: A Systematic Literature Review and Meta-Analysis

Overview

Journal Infect Dis Ther

Specialty Infectious Diseases

Date 2024 Apr 25

PMID 38662332

Authors

Tetsuya Matsumoto

Akira Yuasa

Hiroyuki Matsuda

Dilinuer Ainiwaer

Naohiro Yonemoto

Affiliations

Soon will be listed here.

Abstract

Introduction: Antimicrobial resistance (AMR) is one of the most serious public health challenges worldwide, including in Japan. However, there is limited evidence assessing the AMR burden in Japan. Thus, this systematic literature review (SLR) and meta-analysis (MA) were conducted to assess the clinical and economic burden of AMR in Japan.

Methods: Comprehensive literature searches were performed on EMBASE, MEDLINE, the Cochrane Library, and ICHUSHI between 2012 and 2022 following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. MA estimated a pooled effect between the two comparative arms (AMR vs. non-AMR). The results were reported in measures of odds ratios (ORs) for in-hospital mortality and in standardized mean differences (SMDs) for length of stay (LOS) and direct medical costs.

Results: Literature searches identified 1256 de-duplicated records, of which 56 observational studies (English, n = 35; Japanese, n = 21) were included. Of note, twenty-two studies (39.3%) compared the AMR group with non-AMR group. In the SLR, in-hospital mortality, LOS, and direct medical costs were higher in the AMR group compared to the non-AMR group. Eight studies were selected for the MA. In the AMR group, the pooled estimate showed a statistically higher in-hospital mortality [random effect (RE)-OR 2.25, 95% CI 1.34-3.79; I = 89%; τ = 0.2257, p < 0.01], LOS (RE-SMD 0.37, 95% CI - 0.09-0.84; I = 99%; τ = 0.3600, p < 0.01), and direct medical cost (RE-SMD 0.53, 95% CI 0.43-0.62; I = 0.0%; τ = 0.0, p = 0.88) versus the non-AMR group.

Conclusion: Our study presents an overview of the clinical and economic burden of AMR in Japan. Patients with AMR infections experience significantly higher in-hospital mortality, LOS, and direct medical costs compared with patients without AMR infections.

References

Pulingam T, Parumasivam T, Gazzali A, Sulaiman A, Chee J, Lakshmanan M . Antimicrobial resistance: Prevalence, economic burden, mechanisms of resistance and strategies to overcome. Eur J Pharm Sci. 2021; 170:106103. DOI: 10.1016/j.ejps.2021.106103. View

Ma L, Wang Y, Yang Z, Huang D, Weng H, Zeng X . Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better?. Mil Med Res. 2020; 7(1):7. PMC: 7049186. DOI: 10.1186/s40779-020-00238-8. View

Asai N, Sakanashi D, Suematsu H, Kato H, Hagihara M, Nishiyama N . The epidemiology and risk factor of carbapenem-resistant enterobacteriaceae colonization and infections: Case control study in a single institute in Japan. J Infect Chemother. 2018; 24(7):505-509. DOI: 10.1016/j.jiac.2018.02.005. View

Wozniak T, Barnsbee L, Lee X, Pacella R . Using the best available data to estimate the cost of antimicrobial resistance: a systematic review. Antimicrob Resist Infect Control. 2019; 8:26. PMC: 6359818. DOI: 10.1186/s13756-019-0472-z. View

Egger M, Davey Smith G, Schneider M, Minder C . Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109):629-34. PMC: 2127453. DOI: 10.1136/bmj.315.7109.629. View

Tsuzuki S, Matsunaga N, Yahara K, Gu Y, Hayakawa K, Hirabayashi A . National trend of blood-stream infection attributable deaths caused by Staphylococcus aureus and Escherichia coli in Japan. J Infect Chemother. 2019; 26(4):367-371. DOI: 10.1016/j.jiac.2019.10.017. View

Kaku N, Yanagihara K, Morinaga Y, Yamada K, Harada Y, Migiyama Y . Influence of antimicrobial regimen on decreased in-hospital mortality of patients with MRSA bacteremia. J Infect Chemother. 2014; 20(6):350-5. DOI: 10.1016/j.jiac.2013.12.009. View

Uematsu H, Yamashita K, Mizuno S, Kunisawa S, Shibayama K, Imanaka Y . Effect of methicillin-resistant Staphylococcus aureus in Japan. Am J Infect Control. 2018; 46(10):1142-1147. DOI: 10.1016/j.ajic.2018.04.214. View

Weiner-Lastinger L, Abner S, Edwards J, Kallen A, Karlsson M, Magill S . Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network, 2015-2017. Infect Control Hosp Epidemiol. 2019; 41(1):1-18. PMC: 8276252. DOI: 10.1017/ice.2019.296. View

10.

Miyazaki T, Yanagihara K, Kakeya H, Izumikawa K, Mukae H, Shindo Y . Daily practice and prognostic factors for pneumonia caused by methicillin-resistant Staphylococcus aureus in Japan: A multicenter prospective observational cohort study. J Infect Chemother. 2019; 26(2):242-251. DOI: 10.1016/j.jiac.2019.08.018. View

11.

Cosgrove S, Sakoulas G, Perencevich E, Schwaber M, Karchmer A, Carmeli Y . Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis. 2002; 36(1):53-9. DOI: 10.1086/345476. View

12.

Saito S, Hayakawa K, Tsuzuki S, Ishikane M, Nagashima M, Mezaki K . A Matched Case-Case-Control Study of the Impact of Clinical Outcomes and Risk Factors of Patients with IMP-Type Carbapenemase-Producing Carbapenem-Resistant in Japan. Antimicrob Agents Chemother. 2020; 65(3). PMC: 8092526. DOI: 10.1128/AAC.01483-20. View

13.

Umemura Y, Ogura H, Takuma K, Fujishima S, Abe T, Kushimoto S . Current spectrum of causative pathogens in sepsis: A prospective nationwide cohort study in Japan. Int J Infect Dis. 2020; 103:343-351. DOI: 10.1016/j.ijid.2020.11.168. View

14.

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

15.

Tsuzuki S, Yu J, Matsunaga N, Ohmagari N . Length of stay, hospitalisation costs and in-hospital mortality of methicillin-susceptible and methicillin-resistant Staphylococcus aureus bacteremia in Japan. Public Health. 2021; 198:292-296. DOI: 10.1016/j.puhe.2021.07.046. View

16.

Hanada S, Iwata S, Kishi K, Morozumi M, Chiba N, Wajima T . Host Factors and Biomarkers Associated with Poor Outcomes in Adults with Invasive Pneumococcal Disease. PLoS One. 2016; 11(1):e0147877. PMC: 4731463. DOI: 10.1371/journal.pone.0147877. View

17.

Uematsu H, Yamashita K, Kunisawa S, Fushimi K, Imanaka Y . The economic burden of methicillin-resistant Staphylococcus aureus in community-onset pneumonia inpatients. Am J Infect Control. 2016; 44(12):1628-1633. DOI: 10.1016/j.ajic.2016.05.008. View

18.

Shoji H, Urakawa T, Watanabe K, Hirano T, Katsumi K, Ohashi M . Clinical features, outcomes, and survival factor in patients with vertebral osteomyelitis infected by methicillin-resistant staphylococci. J Orthop Sci. 2016; 21(3):282-6. DOI: 10.1016/j.jos.2016.01.009. View

19.

Amir-Behghadami M, Janati A . Population, Intervention, Comparison, Outcomes and Study (PICOS) design as a framework to formulate eligibility criteria in systematic reviews. Emerg Med J. 2020; 37(6):387. DOI: 10.1136/emermed-2020-209567. View

20.

Aoyagi T, Kaito C, Sekimizu K, Omae Y, Saito Y, Mao H . Impact of psm-mec in the mobile genetic element on the clinical characteristics and outcome of SCCmec-II methicillin-resistant Staphylococcus aureus bacteraemia in Japan. Clin Microbiol Infect. 2014; 20(9):912-9. DOI: 10.1111/1469-0691.12575. View